Clinical Trial of Infusion of Activated NK Cells for the Treatment of Sarcomas

NCT05952310 · tracked via the Priya Life Science Spain tracker

Sponsor

Antonio Pérez Martínez

Phase

Not applicable

Started

2022-10-24

Last updated

2023-07-21

Condition(s) studied

Malignant Sarcoma

Investigational drug(s) / intervention(s)

Natural Killer (NK) cells (a new immunotherapy)

Natural Killer (NK) cells (a new immunotherapy): It is proposed to infuse allogeneic NK cells from a haploidentical donor, after administration of lymphoablative chemotherapy and/or radiotherapy, as a treatment in patients with sarcomas, who have completed conventional treatment but maintain detectable residual disease. The administration of low doses of radiotherapy is aimed at stressing residual tumor cells by increasing the expression of NK cell activating receptor ligands. The administration of prior chemotherapy aims at immunosuppressing the patient, allowing immunotherapy with allogeneic NK cells from haploidentical donor as well as autologous NK cell recovery to lead the immune reconstitution after chemotherapy, prolonging the antitumor effect. In conjunction with NK cell infusion, low doses (1x106/UI/m2) of interleukin 2 (IL-2) will be administered subcutaneously every 48h for a maximum of 6 doses, to favor the expansion and antitumor effect of NK cells.

Study summary

This is an exploratory therapeutic study (according to the terminology of the "ICH Harmonised Tripartite Guideline Topic E8. General Considerations for Clinical Trials". EMEA, March 1998. CPMP/ICH/291/95), open-label, non-randomized, multicenter study. It is considered phase I/II since the safety and efficacy of the infusion of allogeneic haploidentical NK cells in combination with chemotherapy and/or radiotherapy in the treatment of pediatric, adolescent and young adult patients with refractory sarcoma will be sought.

Eligibility

Sex

ALL

Min age

—

Max age

30 Years

Healthy volunteers

Inclusion Criteria: 1. Patients aged between 0 and 30 years diagnosed with malignant sarcoma, who at the end of conventional treatment still have detectable residual disease (based on imaging techniques) or in case of stable disease or minimal disease when there is an absence of clinical benefit from chemotherapy (poor tolerance due to adverse effects related to chemotherapy). 2. Lansky/Karnofsky index \> 60%. 3. Mild-moderate (\<4) organ functional impairment (hepatic, renal, respiratory), according to National Cancer Institute criteria (NCI CTCAE v5.0). 4. Left ventricular ejection fraction \>39%. 5. Adult subjects who voluntarily signed informed consent prior to the first study intervention. 6. Minor subjects whose representative/legal guardian voluntarily signed the informed consent prior to the first intervention of the study. 7. In the case of mature minors (12 - 17 years of age), in addition to the consent signed by the legal guardian, the minor's assent will be obtained. 8. Women of childbearing capacity must have a negative pregnancy test at the time of inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method of contraceptive implant, injectable contraceptive, permanent intrauterine device, sexual abstinence or partner with vasectomy) during their participation in the study and within 30 days of the last visit. 9. Presence of a compatible haploidentical donor (father or mother or sibling). Exclusion Criteria: 1. Patients with a history of poor therapeutic compliance. 2. Patients who, after a psycho-social evaluation, are censored as unsuitable for the procedure. * Socio-familial situation that makes proper participation in the study impossible. * Patients with emotional or psychological problems secondary to the disease, such as post-traumatic stress disorder, phobias, delirium, psychosis, requiring specialist support. * Evaluation of the involvement of family members in the patient's health. * Impossibility to understand information about the trial. 3. Severe functional organ impairment (hepatic, renal, respiratory) (4), according to the criteria of the National Cancer Institute (NCI CTCAE 5.0). 4. Contraindications, interactions, precautions for use and dose reductions indicated in the corresponding data sheets must be considered. 5. Subjects who have been administered other investigational drugs in the 90 days prior to inclusion.

Primary outcome measure(s)

Safety of allogeneic haploidentical adult differentiated Natural Killer cell infusion — Through study completion, an average of 7 years
Safety of infusion of allogeneic haploidentical adult differentiated Natural Killers cells in combination with inteleukin-2 after chemotherapy and radiotherapy. Each patient will be monitored for the detection of possible adverse effects. The Common Terminology Criteria for Adverse Events V5.0 will be followed and the proportion of patients with toxicity will be determined according to the degree of toxicity. The intensity of toxic effects that cannot be classified according to the criteria for toxicity of the aforementioned system will be classified as follows (MedDRA classification): (a) Mild (asymptomatic); b) Moderate (symptomatic but does not significantly interfere with function); c) Severe (causes significant interference with function); d) Life-threatening

Trial sites (1)

Facility	City	Region	Status
Hospital Universitario La Paz	Madrid	Spain	Recruiting

More Antonio Pérez Martínez trials in Spain

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05952310 on ClinicalTrials.gov ↗ ← All trials in Spain